{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:08:40Z","timestamp":1785510520970,"version":"3.56.0"},"reference-count":36,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:p>\n                    <jats:bold>Aim:<\/jats:bold>\n                    Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive form of metabolic dysfunction-associated steatotic liver disease, linked to hepatic and extra-hepatic complications and substantial healthcare costs. Despite its clinical and economic impact, real-world evidence on disease progression and costs in Germany is limited.\n                    <jats:bold>Materials &amp; methods:<\/jats:bold>\n                    We conducted a retrospective cohort study using statutory health insurance claims from the InGef database (2016\u20132023), covering 4.7% of the German population. Patients with MASH were identified using ICD-10-GM code K75.8, in absence of the more specific code in the German coding system. Baseline characteristics and comorbidities were assessed over 2 years prior to index diagnosis. Progression was defined by transitions through end-stage liver disease (ESLD) stages: compensated cirrhosis, decompensated cirrhosis, hepatocellular carcinoma and liver transplantation. Healthcare costs were analyzed descriptively and via regression models.\n                    <jats:bold>Results:<\/jats:bold>\n                    Among 4710 patients with MASH (prevalence: 0.15%), 39.4% had documented ESLD during follow-up (mean follow-up in days 1530). Disease progression to ESLD occurred in 26.0% of patients without baseline ESLD (n\u00a0=\u00a0922\/3490), whereas 4.0% of patients with baseline ESLD (n\u00a0=\u00a048\/1188) progressed to a more severe ESLD stage during follow-up, with a mean time to first progression of approximately 25.3\u00a0months. Patients with ESLD incurred annual costs of \u20ac12,737 versus \u20ac4928 for those without ESLD. Progression to hepatocellular carcinoma and liver transplantation resulted in predicted costs of \u20ac12,948 and \u20ac75,719 per patient-year, respectively. Mortality was significantly higher among patients with ESLD (incidence rate ratio: 4.65; 95% CI: 3.76\u20135.79).\n                    <jats:bold>Discussion:<\/jats:bold>\n                    Over a quarter of identified patients with MASH already had advanced liver disease at baseline, suggesting potential underdiagnosis or late recognition in routine clinical practice. Early detection, proactive management and targeted therapies are essential to reduce progression and economic burden.\n                  <\/jats:p>","DOI":"10.57264\/cer-2026-0092","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T10:58:02Z","timestamp":1784717882000},"source":"Crossref","is-referenced-by-count":0,"title":["Understanding the economic and healthcare burden of metabolic dysfunction-associated steatohepatitis: a real-world claims data analysis from Germany"],"prefix":"10.57264","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-0226","authenticated-orcid":false,"given":"Frank","family":"Tacke","sequence":"first","affiliation":[{"name":"Department of Hepatology &amp; Gastroenterology, Campus Virchow-Klinikum (CVK) &amp; Campus Charit\u00e9 Mitte (CCM), Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Augustenburger Platz 1, D-13353 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yestle","family":"Kim","sequence":"additional","affiliation":[{"name":"Madrigal Pharmaceuticals Inc, Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7872-2060","authenticated-orcid":false,"given":"Jennifer S","family":"Haas","sequence":"additional","affiliation":[{"name":"EU Real World Evidence, Cencora, Lange Laube 31, 30159 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda J","family":"Daumont","sequence":"additional","affiliation":[{"name":"Madrigal Pharmaceuticals GmbH, Oberallmendstrasse 18, 6300 Zug, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Maas","sequence":"additional","affiliation":[{"name":"EU Real World Evidence, Cencora, Lange Laube 31, 30159 Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Madrigal Pharmaceuticals Inc, Barr Harbor Drive, Suite 200, West Conshohocken, PA 19428, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M","family":"Schattenberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Saarland, University Hospital, Kirrberger Str. 100, 66421 Homburg, Saarland, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_9_3_2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review","volume":"32","author":"Chan WK","year":"2023","unstructured":"Chan WK, Chuah KH, Rajaram RB Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J. Obes. Metab. Syndr. 32(3), 197\u2013213 (2023).","journal-title":"J. Obes. Metab. Syndr."},{"issue":"2","key":"e_1_3_9_4_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jama.2025.19615","article-title":"Metabolic dysfunction-associated steatotic liver disease in adults: a review","volume":"335","author":"Tilg H","year":"2026","unstructured":"Tilg H, Petta S, Stefan N Metabolic dysfunction-associated steatotic liver disease in adults: a review. JAMA 335(2), 163\u2013174 (2026).","journal-title":"JAMA"},{"issue":"6","key":"e_1_3_9_5_2","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 79(6), 1542\u20131556 (2023).","journal-title":"J. Hepatol."},{"issue":"5","key":"e_1_3_9_6_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/cld.1061","article-title":"Global epidemiology of chronic liver disease","volume":"17","author":"Cheemerla S","year":"2021","unstructured":"Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin. Liver Dis. (Hoboken) 17(5), 365\u2013370 (2021).","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"e_1_3_9_7_2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"Tacke F","year":"2024","unstructured":"Tacke F, Horn P, Wai-Sun Wong V EASL\u2013EASD\u2013EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81, 492\u2013542 (2024).","journal-title":"J. Hepatol."},{"key":"e_1_3_9_8_2","doi-asserted-by":"crossref","first-page":"111846","DOI":"10.1016\/j.diabres.2024.111846","article-title":"Diabetes as a risk factor for MASH progression","volume":"217","author":"Gancheva S","year":"2024","unstructured":"Gancheva S, Roden M, Castera L. Diabetes as a risk factor for MASH progression. Diabetes Res. Clin. Pract. 217, 111846 (2024).","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"1","key":"e_1_3_9_9_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2337\/dsi23-0010","article-title":"Understanding the burden of nonalcoholic fatty liver disease: time for action","volume":"37","author":"Younossi ZM","year":"2024","unstructured":"Younossi ZM, Henry L. Understanding the burden of nonalcoholic fatty liver disease: time for action. Diabetes Spectr. 37(1), 9\u201319 (2024).","journal-title":"Diabetes Spectr."},{"issue":"4","key":"e_1_3_9_10_2","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.cgh.2025.09.002","article-title":"Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries","volume":"24","author":"Younossi ZM","year":"2025","unstructured":"Younossi ZM, Paik JM, Lazarus JV Projected global clinical, humanistic, and economic impact of metabolic dysfunction-associated steatohepatitis (MASH): the cost of inaction based on data from nine countries. Clin. Gastroenterol. Hepatol. 24(4), 1016\u20131034 (2025).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"e_1_3_9_11_2","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1002\/ejhf.70053","article-title":"Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population","volume":"27","author":"Huber Y","year":"2025","unstructured":"Huber Y, Hofmann L, Prochaska JH Incidence of major cardiovascular events in patients with metabolic dysfunction-associated steatotic liver disease in the general population. Eur. J. Heart Fail. 27, 2490\u20132500 (2025).","journal-title":"Eur. J. Heart Fail."},{"issue":"4","key":"e_1_3_9_12_2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"69","author":"Estes C","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J. Hepatol. 69(4), 896\u2013904 (2018).","journal-title":"J. Hepatol."},{"issue":"10290","key":"e_1_3_9_13_2","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell EE","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 397(10290), 2212\u20132224 (2021).","journal-title":"Lancet"},{"issue":"9","key":"e_1_3_9_14_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1055\/a-1880-2283","article-title":"Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) \u2013 April 2022 \u2013 AWMF-Registernummer: 021\u2013025","volume":"60","author":"Roeb E","year":"2022","unstructured":"Roeb E, Canbay A, Bantel H Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) \u2013 April 2022 \u2013 AWMF-Registernummer: 021\u2013025. Z. Gastroenterol. 60(9), 1346\u20131421 (2022).","journal-title":"Z. Gastroenterol."},{"issue":"6","key":"e_1_3_9_15_2","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1111\/liv.14825","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis","volume":"41","author":"Schattenberg JM","year":"2021","unstructured":"Schattenberg JM, Lazarus JV, Newsome PN Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: a cost-of-illness analysis. Liver Int. 41(6), 1227\u20131242 (2021).","journal-title":"Liver Int."},{"key":"e_1_3_9_16_2","unstructured":"Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte. Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme 10. Revision German Modification Version 2025. (2024). (Access date: 16 June 2026). https:\/\/klassifikationen.bfarm.de\/icd-10-gm\/kode-suche\/htmlgm2025\/index.htm"},{"issue":"8","key":"e_1_3_9_17_2","first-page":"851","article-title":"Frequency of diagnosed non-alcoholic fatty liver disease (NAFLD) in the German population - an analysis based on health insurance data","volume":"59","author":"Stahmeyer JT","year":"2021","unstructured":"Stahmeyer JT, Hemmerling M, Burger B Frequency of diagnosed non-alcoholic fatty liver disease (NAFLD) in the German population - an analysis based on health insurance data. Z. Gastroenterol. 59(8), 851\u2013858 (2021).","journal-title":"Z. Gastroenterol."},{"key":"e_1_3_9_18_2","unstructured":"GKV Spitzenverband. Die gesetzlichen Krankenkassen Ver\u00e4nderungen bei der Anzahl der Krankenkassen (Angaben am Stichtag 1.1.). (2024). (Access date: 6 June 2024). https:\/\/www.gkv-spitzenverband.de\/krankenversicherung\/kv_grundprinzipien\/alle_gesetzlichen_krankenkassen\/alle_gesetzlichen_krankenkassen.jsp"},{"key":"e_1_3_9_19_2","unstructured":"Statistisches Bundesamt (DESTATIS). Bev\u00f6lkerungsstand: Bev\u00f6lkerung nach Nationalit\u00e4t und Geschlecht (Quartalszahlen). (2024). (Access date: 6 June 2024). https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Bevoelkerung\/Bevoelkerungsstand\/Tabellen\/liste-zensus-geschlecht-staatsangehoerigkeit.html"},{"key":"e_1_3_9_20_2","unstructured":"Bundesministerium f\u00fcr Gesundheit. Kennzahlen der Gesetzlichen Krankenversicherung 2011 bis 2024: Kennzahlen und Faustformeln. (2024). (Access date: 20 September 2024). https:\/\/www.bundesgesundheitsministerium.de\/fileadmin\/Dateien\/3_Downloads\/Statistiken\/GKV\/Kennzahlen_Daten\/KF2024Bund_August_2024"},{"issue":"1","key":"e_1_3_9_21_2","doi-asserted-by":"crossref","first-page":"S380","DOI":"10.1016\/j.jval.2025.09.1699","article-title":"HSD38 Economic burden and healthcare resource utilization of metabolic dysfunction-associated steatohepatitis (MASH) in Germany: a claims data analysis","volume":"28","author":"Kim Y","year":"2025","unstructured":"Kim Y, Ramezani T, Maas C HSD38 Economic burden and healthcare resource utilization of metabolic dysfunction-associated steatohepatitis (MASH) in Germany: a claims data analysis. Value in Health 28(1 Suppl. 12), S380 (2025).","journal-title":"Value in Health"},{"issue":"3","key":"e_1_3_9_22_2","first-page":"S188","article-title":"M2Q or something else? The impact of varying case selection criteria on the prevalence estimation of chronic diseases based on outpatient diagnoses in German claims data","volume":"86","author":"Epping J","year":"2024","unstructured":"Epping J, Stahmeyer JT, Tetzlaff F M2Q or something else? The impact of varying case selection criteria on the prevalence estimation of chronic diseases based on outpatient diagnoses in German claims data. Gesundheitswesen 86(Suppl. 3), S188\u2013S195 (2024).","journal-title":"Gesundheitswesen"},{"issue":"8","key":"e_1_3_9_23_2","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-022-01140-y","article-title":"The economic burden of non-alcoholic steatohepatitis: a systematic review","volume":"40","author":"Witkowski M","year":"2022","unstructured":"Witkowski M, Moreno SI, Fernandes J The economic burden of non-alcoholic steatohepatitis: a systematic review. Pharmacoeconomics 40(8), 751\u2013776 (2022).","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"e_1_3_9_24_2","doi-asserted-by":"crossref","first-page":"e70225","DOI":"10.1111\/liv.70225","article-title":"Metabolic dysfunction-associated steatohepatitis diagnosis and management in Germany: insights from an expert consensus panel","volume":"45","author":"Kim Y","year":"2025","unstructured":"Kim Y, Rydqvist P, Ramezani T Metabolic dysfunction-associated steatohepatitis diagnosis and management in Germany: insights from an expert consensus panel. Liver Int. 45(8), e70225 (2025).","journal-title":"Liver Int."},{"key":"e_1_3_9_25_2","unstructured":"US Food & Drug Administration. FDA approves treatment for serious liver disease known as \u2018MASH\u2019. (2025). (Access date: 13 November 2025). https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-serious-liver-disease-known-mash"},{"issue":"2","key":"e_1_3_9_26_2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s12325-024-03085-4","article-title":"Understanding MASH: an examination of progression and clinical outcomes by disease severity in the TARGET-NASH Database","volume":"42","author":"Luthra R","year":"2025","unstructured":"Luthra R, Sheth A. Understanding MASH: an examination of progression and clinical outcomes by disease severity in the TARGET-NASH Database. Adv. Ther. 42(2), 1165\u20131195 (2025).","journal-title":"Adv. Ther."},{"issue":"1","key":"e_1_3_9_27_2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jhep.2020.02.027","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Phase III STELLAR trials","volume":"73","author":"Harrison SA","year":"2020","unstructured":"Harrison SA, Wong VW, Okanoue T Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Phase III STELLAR trials. J. Hepatol. 73(1), 26\u201339 (2020).","journal-title":"J. Hepatol."},{"issue":"6","key":"e_1_3_9_28_2","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase III, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD A Phase III, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N. Engl. J. Med. 390(6), 497\u2013509 (2024).","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"e_1_3_9_29_2","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase III trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I Phase III trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N. Engl. J. Med. 392(21), 2089\u20132099 (2025).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"e_1_3_9_30_2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh S","year":"2015","unstructured":"Singh S, Allen AM, Wang Z Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin. Gastroenterol. Hepatol. 13(4), 643\u2013654; e649 (2015).","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"8","key":"e_1_3_9_31_2","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/atm-20-7179","article-title":"Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany","volume":"9","author":"Canbay A","year":"2021","unstructured":"Canbay A, Kachru N, Haas JS Healthcare resource utilization and costs among nonalcoholic fatty liver disease patients in Germany. Ann. Transl. Med. 9(8), 615 (2021).","journal-title":"Ann. Transl. Med."},{"issue":"4","key":"e_1_3_9_32_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes","volume":"10","author":"Stefan N","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 10(4), 284\u2013296 (2022).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"e_1_3_9_33_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher G","year":"2024","unstructured":"Targher G, Byrne CD, Tilg H. MASLD: a systemic metabolic disorder with cardiovascular and malignant complications. Gut 73(4), 691\u2013702 (2024).","journal-title":"Gut"},{"issue":"1","key":"e_1_3_9_34_2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jhep.2025.08.018","article-title":"New targets and new drugs for hepatobiliary cancers","volume":"84","author":"Chan SL","year":"2026","unstructured":"Chan SL, Lamarca A, Hsu C New targets and new drugs for hepatobiliary cancers. J. Hepatol. 84(1), 213\u2013228 (2026).","journal-title":"J. Hepatol."},{"key":"e_1_3_9_35_2","doi-asserted-by":"crossref","DOI":"10.1007\/s10620-026-10033-5","article-title":"Incidence of cardiovascular events and extrahepatic malignancies in steatotic liver disease subgroups","author":"Pekarska K","year":"2026","unstructured":"Pekarska K, Rowe I, Parker R. Incidence of cardiovascular events and extrahepatic malignancies in steatotic liver disease subgroups. Dig. Dis. Sci. doi: 10.1007\/s10620-026-10033-5 (2026) (Epub ahead of print).","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_9_36_2","unstructured":"Statistisches Bundesamt. Diagnosedaten der Krankenh\u00e4user (Eckdaten der vollstation\u00e4ren Patienten und Patientinnen) 2000\u20132023. (2026). (Access date: 11 June 2026). https:\/\/www.gbe-bund.de:443\/gbe\/isgbe.archiv?p_indnr=550&p_archiv_id=10081766&p_sprache=D&p_action=A"},{"issue":"12","key":"e_1_3_9_37_2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka AC","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J Nonalcoholic steatohepatitis: a review. JAMA 323(12), 1175\u20131183 (2020).","journal-title":"JAMA"},{"key":"e_1_3_9_38_2","first-page":"100386","article-title":"Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review","volume":"41","author":"Sanyal AJ","year":"2024","unstructured":"Sanyal AJ, Husain M, Diab C Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: a systematic review. Am. Heart J. Plus 41, 100386 (2024).","journal-title":"Am. Heart J. Plus"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2026-0092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:25:08Z","timestamp":1785507908000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2026-0092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.57264\/cer-2026-0092"],"URL":"https:\/\/doi.org\/10.57264\/cer-2026-0092","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"article-number":"e260092"}}